Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sigma Of Australia To Report U.S.$254 Million Loss From Past Buys

This article was originally published in PharmAsia News

Executive Summary

Australia's Sigma Pharmaceuticals, reeling from acquisitions it made several years ago, is expected to report a loss for the past year of more than U.S.$254 million

You may also be interested in...



Coronavirus: Can Companies Achieve Vaccine Ambition?

Brilinta Boost For AZ In Stroke Study

Novo Awaits EMA’s Verdict On Oral Form Of Antidiabetic Blockbuster Semaglutide

Alnylam’s Givlaari for acute hepatic porphyria is also among the 14 new products that could get an EU approval recommendation this week.

UsernamePublicRestriction

Register

SC074406

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel